

UCLPartners/CEG Risk Stratification Tool June 2020 – Asthma

This search will identify patients with asthma who are potentially at higher risk of exacerbation. All patients with an asthma diagnosis who have had asthma treatment in the previous 12 months will be included. There are separate searches for patients aged 12-16 year olds and patients aged over 17. The UCLP/CEG search results differ from QOF searches because the UCLP/CEG search includes only those patients registered on the day of the search. QOF ‘rules’ on age-group and exclusions also differ from UCLP/CEG groupings

These patients will then be stratified into 3 groups.

- Group 1 are at greatest risk of exacerbation, and they will fall automatically into the high risk cohort
- Group 2 meet criteria that suggest they may be at higher risk of stratification. They will be stratified further using the ACT Test into high, medium and low risk cohorts.
- Group 3 includes patients who are on ICS or SABA alone with no other risk factors for exacerbation. This group can be phased for later review and risk stratification using the ACT Test.

	Risk Factor	Search period	Comment
Group1	Biologic therapies	Any prescribed in 12m	<u>Omalizumab</u> , <u>mepolizumab</u> , <u>reslizumab</u> , and <u>benralizumab</u> .
	Tiotropium	Any prescribed in 6m	
	Prednisolone	3 or more prescribed in 12m	
	Antibiotics	3 or more prescribed in 12m	Amoxicillin, doxycycline, erythromycin, clarithromycin,
	High dose ICS in LABA/ICS combination	Any prescribed in 6m	
	Montelukast	Any prescribed in 12m	
	Theophylline	Any prescribed in 12m	
Group2	Exacerbation asthma	Acute exacerbation in 12m	
	Prednisolone	Prescribed in 12m	
	Antibiotic	2 or more prescribed in 12m	Amoxicillin, doxycycline, erythromycin, clarithromycin,
	6+ SABA	Prescribed in 12m	
	LABA but no ICS	Any prescribed in 6m	
	3 SABA no ICS	Prescribed in 6m	
Group 3	ICS	Any prescribed in 6m	
	SABA alone	Any prescribed in 12m	